

A study of radiotherapy with or without chemotherapy in primary central nervous system (CNS) lymphoma

Submission date 28/02/2001	Recruitment status Stopped	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 28/02/2001	Overall study status Stopped	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 29/07/2009	Condition category Cancer	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Miss Sally Stenning

Contact details
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA
ss@ctu.mrc.ac.uk

Additional identifiers

Protocol serial number
BR06

Study information

Scientific Title

Study objectives

To evaluate the effect of CHOP chemotherapy on event-free and overall survival.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Primary study design

Interventional

Study design

Randomised controlled trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Cancer

Interventions

Group 1: radiotherapy alone (54 Gy total dose in 27 fractions)

Group 2: radiotherapy as above, followed after 4 weeks by six cycles of CHOP chemotherapy given at 3-week intervals (cyclophosphamide 750 mg/m² iv, adriamycin 50 mg/m² iv, vincristine 1.4 mg/m² iv (max 2 mg) and prednisolone (20 mg po tds for 5 days)

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

CHOP chemotherapy

Primary outcome(s)

Survival.

Key secondary outcome(s)

Event-free survival.

Completion date

01/10/1995

Reason abandoned (if study stopped)

Slow accrual

Eligibility

Key inclusion criteria

1. Pathologically proven primary cerebral lymphoma
2. Aged 18-75
3. No previous radiotherapy or chemotherapy
4. Adequate neurological, physical and mental function

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Upper age limit

75 Years

Sex

Not Specified

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/11/1988

Date of final enrolment

01/10/1995

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre

MRC Clinical Trials Unit

London

United Kingdom

NW1 2DA

Sponsor information

Organisation

Medical Research Council (MRC) (UK)

Funder(s)

Funder type

Research council

Funder Name

Medical Research Council (MRC) (UK)

Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, Medical Research Committee and Advisory Council, MRC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results in: GM Mead, NM Bleehen, A Gregor, J Bullimore, R Rampling, JT Roberts, M Glaser, P Lantos, JW Ironside, TH Moss, M Brada, JB Whaley and SP Stenning for the MRC Brain Tumour Working Party (). A Medical Research Council Randomised Trial in patients with primary cerebral non-Hodgkin lymphoma. Cancer 89(6): 1359-1370	15/09/2000		Yes	No